Urinary monoclonal free light chains in primary Sjögren's syndrome: an aid to the diagnosis of malignant lymphoma

M T WALTERS, F K STEVENSON, A HERBERT, M I D CAWLEY, AND J L SMITH

From the Departments of ¹Rheumatology, ²Immunology, and ³Histopathology, Southampton General Hospital, Tremona Road, Southampton SO9 4XY

SUMMARY Three patients, two with typical primary Sjögren's syndrome (SS) and the third with several features of SS, including abnormal sialography and reduced tear secretion, developed B cell non-Hodgkin's lymphoma (NHL) of parotid or lung, or both. Isoelectric focusing of concentrated urine specimens in agarose, followed by immunofixation, demonstrated the presence in each patient's urine of monoclonal free light chains of the same class as that shown on the tumour cells. In one patient the level of urinary free light chains was monitored and found to correlate with disease activity. Similar techniques showed no monoclonal light chains in the urine from a further 26 cases of SS with no clinical evidence of lymphoma. The detection of monoclonal urinary free light chains may provide an early diagnostic clue to the development of lymphoma in patients with SS and be a means of tumour monitoring.

Key words: salivary glands, lung.

SS is an autoimmune, lymphocyte-mediated disorder characterised in the uncomplicated form by the destruction of exocrine glands and symptoms of mucosal dryness. Thus the hallmarks of the condition are keratoconjunctivitis sicca (KCS) and xerostomia. When there is no other recognised connective tissue disease (CTD) present the condition is called primary SS. When another CTD is associated (most commonly rheumatoid arthritis) the term secondary SS is used. Primary SS may be limited to glandular tissue or it may involve extraglandular sites, resulting in pulmonary disease, arthritis or arthralgia, non-thrombocytopenic purpuric rashes, renal tubular acidosis, and other distinctive clinical and serological abnormalities. ¹

It is well recognised that NHL can develop in both primary and secondary SS, with many case reports to assert this point.²⁻⁶ In a prospective study Kassan et al.⁷ demonstrated an increased risk for the development of NHL of 43.8 times for SS patients

compared with controls. An increased risk of Waldenström's macroglobulinaemia³ 7 and myeloproliferative disorder⁸ are also reported, and there is one recorded case of light chain myeloma development.⁹

B Cell NHL arises from a clonal proliferation of neoplastic B lymphocytes and may often reflect properties of normal B lymphocytes 'frozen' at a particular point in differentiation. Until recently it was thought that such cells synthesised immunoglobulin (Ig) only for insertion into the cell membrane and were incapable of secreting Ig. However, in-vitro studies on neoplastic B cells from patients with NHL and chronic lymphocytic leukaemia (CLL) have shown that these cells are capable of secreting small amounts of immunoglobulin for export, often with an excess of light chain production. ¹⁰ If sufficient tumour load is present this light chain might be expected to be found in the urine. ¹¹

Previous work in this unit with the highly sensitive technique of isoelectric focusing of concentrated 24-hour urine specimens in agarose, followed by immunofixation, has shown small amounts of monoclonal light chain, of the same type as that displayed

Accepted for publication 29 July 1985.

Correspondence to Dr M T Walters, Department of Rheumatology, Southampton General Hospital, Tremona Road, Southampton SO9 4XY.

at the tumour cell surface, in the urine of 44% and 74% of patients studied with NHL and B cell CLL respectively. No patient had a monoclonal immunoglobulin band detectable in either serum or concentrated urine when analysed by electrophoresis or immunoelectrophoresis. It was possible in two cases to show unequivocally that the urinary light chain was produced by the tumour cells. 12

We present the findings of two patients with typical primary SS, one of whom developed malignant pulmonary lymphoma and the other malignant parotid lymphoma and a third patient with lymphocytic infiltration of the parotid gland and features of SS, who was subsequently shown to have malignant parotid and pulmonary lymphomata. In the urine from all three cases monoclonal light chains of one type were found by the method described¹² and were associated with and aided the diagnosis of lymphoma. This non-invasive technique may be important in the early diagnosis of B cell neoplasia in SS.

Patients and methods

PATIENT 1

This patient presented in 1982 at the age of 69 with a 13-year history of a non-erosive, symmetrical polyarthritis. Her sicca symptoms consisted of severe xerostomia, KCS, and vaginal dryness. Oral prednisolone was commenced in 1973 but was changed to ACTH injections due to the development of Cushingoid features. Investigation of frequent urinary infections led to a diagnosis of renal tubular acidosis. Other relevant features included recurrent transient parotid swellings, non-thrombocytopenic purpuric rashes, and multiple antibiotic allergies. Serological abnormalities included a sheep cell agglutination titre (SCAT) of 1/512, antinuclear antibodies (ANA) by indirect immunofluorescence (DNA binding normal), SS-A (Ro) and SS-B (La) antibodies, but no organ-specific antibodies.

In 1976 exertional dyspnoea developed. Chest x-ray (CXR) showed diffuse bilateral lower lobe shadowing and an ^{81m}Kr, ^{99m}Tc ventilation/perfusion scan showed matched patchy abnormalities. Pulmonary function tests showed a diminished transfer factor (TF), and a presumptive diagnosis of pulmonary fibrosis was made. In 1982 owing to progressive dyspnoea, transbronchial and then open lung biopsies were performed.

In 1983 death followed relentless progression of the pulmonary disease, despite four-months' treatment with chlorambucil and an increased dose of steroids. A postmortem examination was not performed.

PATIENT 2

This patient developed polyarthralgia in 1972 at the age of 22. One year later she had an unexplained episode of pulmonary consolidation. In 1976 an acute right parotitis occurred, and a 10-year history of intermittent swelling of the right parotid gland was noted. Treatment with penicillin was instituted, but the gland remained enlarged and subsequently a parotidectomy was performed. Light microscopy showed an intense lymphocytic infiltrate, interpreted at that time as the benign lymphoepithelial lesion of SS.

When seen in June 1982, aged 34, she described Raynaud's phenomenon and had trophic changes affecting several fingers of the left hand. A nonerosive synovitis involved the hands, knees, and ankles. Photosensitivity and intermittent, transient purpuric rashes affecting the arms and legs were noted. She suffered from severe xerostomia and xerophthalmia. Examination showed no evidence of salivary gland enlargement or lymphadenopathy. Serological abnormalities included a SCAT of 1/64, ANA by indirect immunofluorescence (DNA binding normal), SS-A, SS-B, and smooth muscle antibodies. The C4 component of complement was reduced at <0.05 g/l, and cryoprecipitate was present in the serum. Monoclonal kappa (K) free light chains were present in the urine.

She was not dyspnoeic and the CXR was normal, but the pulmonary carbon monoxide TF was reduced at 4.59 mmol/min/kPa (predicted 8.3).

In March 1984 there was deterioration in her general clinical condition and staphylococcal pneumonia. She had previously suffered repeated episodes of lower respiratory infection. After resolution of the pneumonia plasmapheresis was initiated for worsening digital ischaemia (attributed to the cryoglobulinaemia), but little improvement followed. Cyclophosphamide was commenced in September, resulting in significant clinical improvement and a marked fall in urinary light chain excretion. It was not possible to obtain a lung biopsy.

PATIENT 3

In 1975 this 68-year-old male was found to have diffuse bilateral patchy pulmonary shadowing on a routine CXR taken during the course of radiotherapy for a basal cell carcinoma of the nose. Pulmonary function tests showed normal ventilatory capacity but a reduced TF at 6.4 mmol/min/kPa (predicted 8.75). A 10-year history of recurrent bilateral parotid swelling was noted, and several subsequent parotid sialograms confirmed main duct ectasia and sacculation, with diminished parotid secretions. The results of Schirmer's tests were 3 mm and 7 mm at five minutes.

By 1979 TF had fallen to 5.54 mmol/min/kPa (predicted 7.9), but CXR appearances were unchanged.

In February 1982 a right parotid abscess occurred after acute parotitis. At surgery a calculus was removed from the main duct, and biopsy showed an intense mononuclear cell infiltrate, associated with loss of parenchyma and one epimyoepithelial island. Autoantibodies were absent from the serum. TF had fallen to 3.84 mmol/min/kPa, and the previous CXR changes had progressed, with extensive bilateral interstitial shadowing and focal consolidation and cavitation on the right. Transbronchial biopsy and bone marrow examination were performed, but no treatment was instituted at this stage.

In February 1983 there was rapid progression of the lung disease and clinical deterioration, with bilateral inguinal and axillary lymphadenopathy. Despite intensive treatment with steroids, he died.

IMMUNOHISTOLOGY

Sections of routine formalin fixed, paraffin embedded material were examined for immunoglobulin determinants by methods previously described.¹³ ¹⁴

CELL MARKER ANALYSIS

Fresh biopsy material was minced through sterile wire mesh, followed by washing in minimal essential medium containing heparin (MEM, Gibco Ltd). Cell suspensions were prepared from biopsy material, blood, and marrow by density gradient

centrifugation over Lymphoprep (Nyegaard and Co. AS, Oslo, Norway) as previously described. 15 Cells collected at the interface were washed three times in phosphate-buffered saline, and viability tested by trypan blue exclusion. After incubation at 37°C for 60 min (to remove extraneous Ig) the cells were washed in MEM containing 20% bovine serum albumin. T Lymphocytes were identified in suspension by immunofluorescence with the mouse monoclonal antibody OKT11, 16 in an immunoperoxidase method with the pan T cell mouse monoclonal antibody UCHT1¹⁷ and on cytocentrifuge preparations by the spontaneous sheep erythyrocyte rosette test (E). 15 Surface and cytoplasmic Ig was identified in a direct immunofluorescence test with fluoresceinconjugated polyclonal rabbit antisera (Dako Ltd) to Ig heavy and light chain determinants as previously described.14

URINE IMMUNOGLOBULIN

Concentrated urine samples were analysed for monoclonal free light chain by the method of isoelectric focusing in agarose, followed by immunofixation, as described previously by two of the present authors (FKS and JLS). ¹² Levels of urinary light chain were measured in 24-hour urine collections by the enzyme linked immunosorbent assay as described previously. ¹⁸

SERUM IMMUNOGLOBULIN

Serum immunoglobulins G, A, and M and complement C3 and C4 were measured by laser nephelo-

Table 1 Cell marker analysis

Patient	Specimen	T Cell		B Cell			
		E Rosettes	MAb*	Surface Ig			Cytoplasmic Ig
				Heavy chain	Ligh chair K		(Ig class)
1 (1982)	Biopsy (lung)	75	90 (OKT11)	NT	7	3	15 (KK)
	Blood	NT^{\ddagger}	NT	NT	3	2	0
	Marrow	42	NT	NT	3	2	211
2	Blood (1) [†]	52	NT	GMD [§]	21	1	0
	Blood (2)	NT	80 (UCHT1)	NT	10	4	0
	Marrow	NT	NT`	NT	10	8	1"
3 (1982)	Blood	40	NT	NT	1	4	20 (Mλ)
- ()	Marrow	58	NT	NT	1	3	5 ^{IL}

All figures are expressed as percentages.

MAb=monoclonal antibody.

[†] Blood (1) examined in 1982; blood (2) examined with marrow in 1984.

^{*} NT=not tested.

[§] Cells staining for G 7%, M 18%, D 20%.

[&]quot; Cells cytoplasm positive for κ or λ ; no monoclonal population.

metry (Hyland). Immune complexes were measured by nephelometry after precipitation with 2% polyethylene glycol.

Results

HISTOLOGY AND CELL MARKER ANALYSIS (Table 1)

Patient 1

Transbronchial biopsy showed a heavy lymphocytic infiltration of the bronchial wall and an interstitial infiltration consisting of lymphocytes and histiocytes. No interstitial fibrosis was present. The appearance was highly suggestive of malignant lymphoma. Open lung biopsy confirmed malignant lymphoma with a pattern of infiltration identical to that described as lymphocytic interstitial pneumonia (LIP). The histological classification was diffuse follicle centre cell lymphoma with plasmacytic differentiation arising in mucosa-associated lymphoid tissue (MALT) (Fig. 1). Immunohistochemical staining showed a predominant cytoplasmic (15%) IgMK lymphoplasmacytoid and plasma cell population (Figs 2a and b).

Patient 2

Review of the right parotidectomy specimen (1976) showed a follicle centre cell lymphoma with plasmacytic differentiation and appearances typical of primary malignant lymphoma arising in MALT





Fig. 1 Diffuse infiltration of alveolar walls by malignant lymphoma (patient 1) (H and E, \times 70).






Fig. 2 Plasmacytoid cells positive for (a) kappa light chain and negative for (b) lambda light chain (patient 1). (Immunoperoxidase stain, ×110).

(Fig. 3). Immunohistochemistry showed a monotypic B cell population producing IgMK (Figs 4a and b).

Patient 3

Analysis of peripheral blood lymphocytes showed a monotypic B cell population with cytoplasmic IgM lambda (λ). An iliac crest marrow aspirate was normal, and a trephine biopsy specimen showed an occasional lymphoid follicle but no evidence of lymphoma. Immunohistochemistry of the bone marrow was not performed.

Transbronchial biopsy showed a dense lymphocytic infiltration (with some histiocytes and centrocytes) invading lung and bronchial epithelium. interpreted as malignant lymphoma. There was insufficient lung and parotid biopsy tissue for immunohistochemical assessment.




Fig. 3 Infiltration of salivary gland tissue by malignant lymphoma with surviving epimyoepithelial islands (patient 2). (H and $E, \times 280$).

Postmortem examination showed extensive infiltration of both lungs by malignant lymphoma. Both parotids showed lymphoma, largely periductal, without evidence of sialadenitis in unaffected surrounding acini. Immunohistology of paraffin embedded tissue confirmed a monotypic IgMλ cell population. The malignant lymphoma showed a distribution within the lung and parotids typical of malignant lymphoma involving MALT. There was no involvement of lymph nodes, liver, or spleen.

IMMUNOCHEMISTRY (Table 2) Patient 1 had 2.8 mg/24 h of monoclonal K free light chain present in her urine at the time of diagnosis of malignant lymphoma.

Patient 2 had a urinary excretion of monoclonal K free light chain of 143 mg/24 h in October 1983,




Fig. 4 Plasmacytoid cells positive for (a) kappa light chain and negative for (b) lambda light chain (patient 2). (Immunoperoxidase stain, ×280).

Table 2 Immunochemistry

Patient	Serum	immunoglo	bulins •	Electrophoresis	Comple	ment*	Immune complexes [†]	Urinary
	G	Α	М		C3	C4		light chain (mg/24 h)
1 (1982)	8-3	1.0	2.8	Normal	1.07	<0.04	IgG 0-717 IgM 1-426	K 2⋅8
2 (1983)	10-1	0.5	1.4	IgMK+K (trace)	0-41	<0.05	IgG 1·145 IgM 0·642	K 143
3 (1982)	4-4	1.2	28.7	IgMλ	1.27	0.18	IgM 1·20	λ32·2

^{*}Normal ranges (g/l): IgG = 7.5 - 16.7; IgA = 0.9 - 4.5; IgM = 0.4 - 3.7; C3 = 0.89 - 2.09; C4 = 0.12 - 0.53.

^{*}Undetectable in normal serum.

Table 3 Control patient results

Patient	Sex	Age (years)	Age Schirmer's (years) test (mm/5 min)	r's 1/5 min)	van Bijsterveld score	rveld	Tear break-up time (s)	(s)	Stimulated parotid rate (ml/min)	Parotid sialogram	99mTc pertechnetate salivary	Associated abnormalities
			T	R	7	R		8			ımagıng	
Primary	SS											
، ا	ir (i	65 2	v e	۰ د	9 -	v -	7	4 4	0	Gross sialectasis	Abnormal	Parotid swellings, anti-Ro, anti-La
1	-	5	t	-	-	-	-	,	o .	main ducts with punctate	Aulionilla	Allu-No, allu-La, positive np otopsy
3	ī	29	∞	-	2	_	4	4	6.0	Statectasis Dilated ducts	Normal	Rhinitis sicca, lip biopsy—chronic
												inflammatory cell infiltration and periductal fibrosis
Probable Primary SS	SS											
4	н Э	65	2	4	4	3	×	2	1.5	Marked duct irregularity	Normal	Parotid swellings, anti-Ro, purpuric
v	נו	9	9	r	-	•	5	7		and saccular dilatation	A 1	rashes, polymyositis, acrocyanosis
. •	<u>.</u> [<u>.</u>	36	3 2	30		-	2 2	9 9	1.1	Punctate sialectasis	Abnormal	royarumus Anti-Ro, anti-La, polyarthritis,
t	L	(,	-	c	t				rashes, parotid swelling
~ &	т (т	2 2	4 κ	7		4 w	ж 4	<i>S</i>	1.27 2.2	Normal Normal	Normal Normal	Rhimitis sicca Raynaud's, SCAT 1/2048
Secondary SS	SS A											
6	Σ	54	-	-	7	9	2	2	2.65	Dilatation/sacculation of	Abnormal	RA
9	2	07	7	,	,	,	2	-	0 0	main ducts	A 1	4
2 =	Σ	8 8	o (n	c 2	n —	J 4	21	<u> </u>	2.7	Duct irregularity, punctate	Abnormal	RA RA
			ı	l	ı		ļ		I	sialectasis		
12	Σ	29	10	∞	4	3	12	01	1.8	Gross duct dilatation	Abnormal	RA
13	ഥ	65	14	15	3	S	4	3	1.3	Early sialectasis	Abnormal	RA, enlarged SM glands
4	ш	62	-	2	7	3	01	01	1.2	Shrunken gland, narrow	Normal	RA vasculitis, enlarged SM glands
15	ίΤ	50	x	7	~	2	œ	4	1.25	Poor emptying	Normal	BA
16	· Œ	57	4	1 ∞	, m	n 6	· =	7	0.26	Marked irregularity and	ΥZ	RA
										sacculation of main ducts		
17	Ľ,	3	35	15	_	_	01	10	1.2	Sialectasis	Abnormal	RA
<u>81</u>	וידו	62	-	4	_	<i>د</i> ر ا	S	9	2.7	Normal	Abnormal	RA, rhinitis sicca
61	נדי נ	S (2	o ·	0 (9 (ς.	∞ :	s S	1.9 . 9.	Minimal duct irregularity	Abnormal	Sarcoidosis/polyarthritis
3 €	ı, (<u>ک</u> د	- - ,	7 (7 4	٠,	2	2,	<u>.</u>	Irregularity of main ducts	Abnormal	KA
17 22	r (r	ς γ	n (r	n (r	v 4	J 4	× ×	o v	7	Normal	Abnormal Normal	RA/SLE Oliocarthritis? RA
33	, (I	3 2	. "	, <u>c</u>	4	ب، ج	۲	, =	<u>.:</u>	Poor emptying	Normal	RA
24	· Œ	8	9	'n		, rc	2	2	1.4	Normal	Abnormal	RA
25	ĹŦ,	99	4	2	3	2	4	4	1.3	Normal	Ϋ́Z	RA
56	īТ	72	2	7	-	2	9	9	2.4	Dilated main duct and	z	RA
										intraglandular ducts with diminished branching		

NA=not available.




Fig. 5 Reduction in urinary monoclonal light chain excretion and clinical improvement after cyclophosphamide treatment (patient 2).

rising to 946 mg/24 h by March 1984, associated with clinical deterioration. A reduction in urinary light chain excretion and clinical improvement followed cyclophosphamide treatment (Fig. 5).

Patient 3 had an IgM λ paraprotein band on serum electrophoresis (EP), and his urine contained 32·2 mg/24 h of monoclonal λ free light chain.

CONTROLS (Table 3)

Eight patients with definite or probable primary SS and 18 patients with secondary SS and no clinical evidence of lymphoma were examined for the presence of urinary monoclonal free light chains. Diagnostic criteria for primary SS were the presence of KCS (two of the following abnormalities: Schirmer's test <10 mm at 5 min, van Bijsterveld score ≥ 4 , tear break-up time <10 s) and xerostomia (two of the following abnormalities: parotid saliva flow rate <1 ml/min under maximal stimulation with lemon juice, ¹⁹ 20 abnormal sialography, abnormal salivary radionuclide imaging). Several patients also had other characteristic clinical features and serological abnormalities, which included anti-Ro and anti-La antibodies. Lip biopsy was not performed routinely but was abnormal in control patients 2 and 3. Secondary SS was present when either KCS or xerostomia, or both, were present with another connective tissue disease. Monoclonal free light chains were not detected in any patient's urine.

Discussion

The malignant lymphomas associated with SS are

usually B cell neoplasms producing monoclonal IgMK and occasionally IgM λ . These lymphomas often run an indolent course, involve a wide variety of tissues, and may be compatible with many years free of symptoms. Diagnosis is often difficult, because as with other malignant lymphomas of MALT the histological appearance is often deceptively benign, and they tend to remain localised for a long time. 23 24

The term 'benign lymphoepithelial lesion' introduced by Godwin in 1952²⁵ is no longer tenable to describe the histological appearance of the salivary gland in SS, as Schmid²⁶ has shown that the cellular infiltrates frequently contain monotypic populations of B cells.

Lymphocytic infiltration of the lungs in SS is well recognised. Strimlan *et al.*²⁷ reviewed 343 SS patients and found pulmonary involvement in 9%. The term 'lymphocytic interstitial pneumonia' was introduced by Carrington and Liebow²⁸ to imply diffuse pulmonary infiltration by lymphocytes and plasma cells but without histological characteristics generally accepted as malignant, though progression to malignant lymphoma has been recognised.^{29–33} The present authors believe that the histopathology of LIP is typical of malignant lymphomas of MALT and that differences between this type of lymphoma and nodal lymphomas account for the difficulties in diagnosis.^{24–34}

The precise diagnosis of malignant B cell lymphoma requires immunohistochemical methods to demonstrate monoclonal immunoglobulin production by lymphocytes. ²⁶ ²⁹ Peripheral blood lymphocytes may show a normal distribution of immunoglobulin surface markers on B lymphocytes and serum and urine EP can be normal. Biopsy material

may be readily accessible from superficially affected tissues, e.g., lymph nodes, but is more difficult to obtain when deeper structures are involved, particularly the lungs. Furthermore, the indolent progression of pulmonary lymphoma, as illustrated by these three cases, leads to irreversible lung damage, which might have been arrested by early recognition and treatment.

Thus a dilemma may arise when lymphoma is suspected but all conventional non-invasive tests are normal. The finding of a tumour-related product in the urine should lead to the institution of a more diligent search for NHL.

The rationale for measuring urinary light chains to detect malignant lymphoma, and in established disease as an indicator of tumour load, has been discussed by Stevenson. Stevenson, Spellerberg, and Smith¹² have developed a highly sensitive technique of isoelectric focusing in agarose, followed by immunofixation, that enables minute quantities (0.03 mg of light chain per 24-hour urine specimen) of monoclonal light chain to be detected against the normal polyclonal excretion of light chain. By this method they have shown that in the B lymphocyte diseases of CLL and NHL the majority of patients tested had monoclonal K or λ light chains present in their urine, which could be shown to be products of the malignant cells. 12

In a study with sensitive electrophoresis combined with immunofixation on sera from 21 patients with primary SS Moutsopoulos et al. found free monoclonal λ light chains in 14 (67%); no urine analyses were reported.³⁶ This suggests that very large amounts of λ light chain were being synthesised. since investigations on CLL showed that secreted free light chain was cleared rapidly from the circulation and could be detected only in the urine. 18 Our three patients similarly showed good clearance, with only a trace of monoclonal K light chain found in the serum of patient 2. Also our small study would not suggest a special role for λ light chains in SS as suggested by Moutsopoulos et al., since two out of three produced K chains.

In a more recent paper Moutsopoulos et al. 37 have investigated serum and urine of patients with primary SS. The incidence of homogeneous protein bands in serum (47%) and urine (76%) of such patients seems very high. In fact they report that 100% of patients with extraglandular SS showed such bands in the urine, sometimes with multiple bands. In our examination of 26 patients with SS (some of whom had extraglandular symptoms) (Table 3) and no evidence of a transition to lymphoma, by a technique which distinguishes monoclonal from polyclonal light chain, we found no evidence for monoclonal light chains in the urine.

Our experience with NHL suggests that such light chains can only be found in urine when there is sufficient tumour load.

The striking and common clinical feature of all three patients we have reported is pulmonary disease with slow clinical progression. Patient 1 had respiratory symptoms for 11 years before her eventual rapid demise from malignant pulmonary lymphoma and had been mistakenly diagnosed as having pulmonary fibrosis. There were no changes in her serum immunoglobulins, serum EP, or peripheral blood and bone marrow lymphocyte markers. It was the finding of K free light chains in her urine, in conjunction with lymphocytic infiltration of the bronchial mucosa, that prompted an open lung biopsy, enabling diagnosis of a follicle centre cell lymphoma.

Patient 2 had a malignant clone of B cells within the parotidectomy specimen taken in 1976, despite the apparently benign appearance on light microscopy. Although only a faint IgMK serum paraprotein band was present, monoclonal K free light chains were present in her urine. Peripheral blood lymphocyte analysis also showed predominant staining for IgMK. However, a bone marrow examination was normal. This patient suffered several unexplained episodes of pneumonia, with a progressive fall in TF despite a normal CXR. These observations raised the possibility of lymphomatous infiltration of the lungs, which has still not been proved histologically. The curious increase in urinary light chain excretion associated with the staphylococcal pneumonia is not easily explained. It was not due to renal protein leakage, as no other serum proteins were present in the urine. It is possible that the pneumonia was a result of compromised immune function as a result of relapse in her lymphoma. Urinary light chain levels fell as the pneumonia resolved but then rose again with further deterioration in her clinical condition. The levels did not fall with plasmapheresis but fell during treatment with cyclophosphamide, and her general condition improved.

Patient 3 was known to have pulmonary infiltrates for at least eight years and was relatively asymptomatic until the final stages of his disease when there was rapid progression of pulmonary lymphoma associated with depression of serum IgG, increase of serum IgM, an IgM\(\lambda\) paraprotein band, a monotypic B cell population in the peripheral blood, and monoclonal λ free light chains in the urine. The salivary gland lesion was subsequently shown to be malignant lymphoma.

In these three cases no single serological or haematological test was able to predict the presence of the eventually proved malignant lymphoma.

However, monoclonal urinary free light chain excretion was a constant finding. The finding of light chains in the urine of patients with leukaemia and lymphoma has been recognised for several years, but the methods of detection were insensitive and clinical disease already apparent. We suggest that the detection of monoclonal free light chains in the urine of SS patients by the sensitive, non-invasive method described should lead to a careful search for malignant lymphoma, especially if there is evidence of pulmonary disease. This is further supported by our own failure to detect urinary free light chains in eight further patients with definite or probable primary SS (some with extraglandular features) and 18 others with secondary SS, all without clinical evidence of lymphoma. These preliminary observations indicate the need for a more extensive prospective study of urinary free light chains in SS.

We would like to thank Mrs Rajee Goswami and Mrs Myf Spellerberg for performing the immunochemistry tests and Miss Pauline Longman for secretarial assistance.

References

- 1 Moutsopoulos H M, moderator. NIH conference: Sjögren's syndrome (sicca syndrome): current issues. Ann Intern Med 1980: 92: 212-6.
- 2 Strand V, Talal N. Advances in the diagnosis and concept of Sjögren's syndrome (autoimmune exocrinopathy). Bull Rheum Dis 1980; 30: 1046-52.
- 3 Anderson L G, Talal N. The spectrum of benign to malignant lymphoproliferation in Sjögren's syndrome. *Clin Exp Immunol* 1971; **9:** 199–221.
- 4 Diaz-Jouanen E, Ruiz-Arguelles G J, Vega-Ortiz J M, Villareal G, Alarcon-Segovia D. From benign polyclonal to malignant monoclonal lymphoproliferation in a patient with primary Sjögren's syndrome. Arthritis Rheum 1981; 24: 850-3.
- 5 Pagani J J, Collins J D, Reza M J. Sjögren's syndrome presenting as pulmonary pseudolymphoma. Report of a case. J Natl Med Assoc 1979; 71: 677-8.
- 6 Ryan G P, James R A, Milazza S C. Malignant lymphoma complicating Sjögren's syndrome. Aust NZ J Med 1974; 4: 287-91.
- 7 Kassan S S, Thomas T L, Moutsopoulos H M, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978; 89: 888-92.
- 8 De Couteau W E, Katakkar S B, Skinnides L, Hayton R C, Somerville E A. Sjögren's syndrome terminating as a myeloproliferative disorder. J Rheumatol 1975; 2: 331-5.
- 9 Shearn M A, Moutsopoulos H M, Sawada S, Gak C. Sjögren's syndrome with light chain myeloma. West J Med 1975; 123: 496-7
- Gordon J, Howlett A R, Smith J L. Free light chain synthesis by neoplastic cells in chronic lymphocytic leukaemia and non-Hodgkin's lymphoma. *Immunology* 1978; 34: 397-404.
- 11 Pierson J, Darley T, Stevenson G T, Virji M. Monoclonal immunoglobulin light chains in urine of patients with lymphoma. Br J Cancer 1980; 41: 681-8.

- 12 Stevenson F K, Spellerberg M, Smith J L. Monoclonal immunoglobulin light chains in the urine of patients with B lymphocytic disease. Its source and use as a diagnostic aid. Br J Cancer 1983; 47: 607–12.
- 13 Mepham B L, Frater W, Mitchell B S. The use of proteolytic enzymes to improve immunoglobulin staining by the PAP technique. *Histochem J* 1979; 11: 345-58.
- 14 Gregg E O, Al-Saffar N, Jones D B, Wright D H, Stevenson F K, Smith J L. Immunoglobulin negative follicle centre cell lymphoma. Br J Cancer 1984; 50: 735-44.
- 15 Payne S V, Smith J L, Jones D B, Wright D H. Lymphocyte markers in non-Hodgkin's lymphomas. Br J Cancer 1977; 36: 57-64
- 16 Verbi W, Greaves M F, Schneider C, et al. Monoclonal antibodies OKT11 and OKT11A have pan T reactivity and block sheep erythrocyte 'receptors'. Eur J Immunol 1982; 12: 81-6
- 17 Beverley P C L, Callard R E. Distinctive functional characteristics of human T lymphocytes defined by E rosetting or a monoclonal T cell antibody. Eur J Immunol 1981; 11: 329–34.
- 18 Tutt A L, Stevenson F K, Smith J L, Stevenson G T. Antibodies against urinary light chain idiotypes as agents for detection and destruction of human neoplastic B lymphocytes. J Immunol 1983; 131: 3058-63.
- 19 Stephen K W, Speirs C F. Methods for collecting individual components of mixed saliva: the relevance to clinical pharmacology. *Br J Clin Pharmacol* 1976; 3: 315-9.
- 20 Whaley K, Williamson J, Chisholm D M, Webb J, Mason D K, Buchanan W W. Sjögren's syndrome. 1. Sicca components. Q J Med 1973; 166: 279–304.
- 21 Faguet G B, Webb H H, Agee J F, Ricks W B, Sharbaugh A H. Immunologically diagnosed malignancy in Sjögren's pseudolymphoma. Am J Med 1978; 65: 424-9.
- 22 Zulman J, Jaffe R, Talal N. Evidence that the malignant lymphoma of Sjögren's syndrome is a monoclonal B cell neoplasm. N Engl J Med 1978; 299: 1215-20.
- 23 Wright D H, Isaacson P G. In: Biopsy pathology of the lymphoreticular system. London. Chapman and Hall, 1983: 267-305, 310-21.
- 24 Herbert A, Wright D H, Isaacson P, Smith J L. Primary malignant lymphoma of the lung; histopathologic and immunologic evaluation of 9 cases. *Hum Pathol* 1984; 15: 415-22.
- 25 Godwin J T. Benign lymphoepithelial lesion of the parotid gland (adenolymphoma, chronic inflammation, lymphoepithelioma, lymphocytic lesion, Mikulicz's disease): report of 11 cases. Cancer 1952; 5: 1089–103.
- 26 Schmid U, Helbron D, Lennert K. Development of malignant lymphoma in myoepithelial sialadenitis (Sjögren's syndrome). Virchows Arch [Pathol Anat] 1982; 395: 11-43.
- 27 Strimlan V C, Rosenow E C, Divertie M B, Harrison E G. Pulmonary manifestations of Sjögren's syndrome. Chest 1976; 70: 354-61.
- 28 Carrington C B, Liebow A A. Lymphoid interstitial pneumonia [Abstract]. Am J Pathol 1966; 48: 36a.
- 29 Banerjee D, Ahmad D. Malignant lymphoma complicating lymphocytic interstitial pneumonia: A monoclonal B cell neoplasm arising in a polyclonal lymphoproliferative disorder. *Hum Pathol* 1982: 13: 780-2.
- 30 Scully R E, Galdabini J J, McNeely B U. Case records of the Massachusetts General Hospital Case 13. N Engl J Med 1980; 302: 795-803.
- 31 Halprin G M, Ramirez J, Pratt P C. Lymphoid interstitial pneumonia. *Chest* 1972; **62**: 418-23.
- 32 Kradin R L, Mark E J. Benign lymphoid disorders of the lung with a theory regarding their development. *Hum Pathol* 1983; 14: 857-67.
- 33 Colby T V, Carrington C B. Lymphoreticular tumours and infiltrates of the lung. In: Summers S C, Rosen P P, eds. *Pathology Annual* Connecticut: Appleton-Century-Crofts, 1983; 18 (part 1): 27-70.

- 34 Herbert A, Walters M T, Cawley M I D, Godfrey R C. Lymphocytic interstitial pneumonia identified as lymphoma of muscosa associated lymphoid tissue (MALT). J Pathol 1985; 146: 129-38.
- 35 Stevenson G T. Biochemical abnormalities in some human neoplasms. (2) Multiple myeloma and other B cell neoplasms. In: Symington T, Carter R L, eds. Scientific foundations of oncology. London: Heinemann, 1976: 85.
- 36 Moutsopoulos H M, Steinberg A D, Lane H C, Papadopoulos N M. High incidence of free monoclonal lambda light chains in the sera of patients with Sjögren's syndrome. J Immunol 1983; **130:** 2663-5.
- 37 Moutsopoulos H M, Costello R, Drosos A A, Mavridis A K, Papadopoulos N M. Demonstration and identification of monclonal proteins in the urine of patients with Sjögren's syndrome. Ann Rheum Dis 1985; 44: 109-12.